Table 19. One-, Two-, Five-,
And Ten-Year Observed And Relative Survival Ratesa
For Selected Malignant Brain and Central Nervous System Tumors, SEER 1973-1999
|
Histology |
ICDO Code(s) |
No. of Cases |
1-Year
|
2-Year
|
5-Year |
10-Year
|
||||
|
|
|
Obs |
Rel |
Obs |
Rel |
Obs |
Rel |
Obs |
Rel |
|
|
Pilocytic astrocytoma |
9421-9422 |
895 |
94.7 |
94.9 |
92.9 |
93.3 |
88.9 |
89.7 |
85.6 |
87.1 |
|
Diffuse astrocytoma |
9410, 9420 |
659 |
72.7 |
73.4 |
60.3 |
61.4 |
44.6 |
46.9 |
34.1 |
38.1 |
|
Anaplastic astrocytoma |
9401, 9411 |
1,998 |
59.7 |
60.4 |
43.3 |
44.4 |
28.0 |
30.0 |
19.4 |
22.7 |
|
Astrocytoma, NOS |
9400 |
6,964 |
58.2 |
59.0 |
45.0 |
46.4 |
33.6 |
36.3 |
25.1 |
29.9 |
|
Glioblastoma |
9440-9442, 9481 |
13,733 |
28.1 |
28.8 |
8.2 |
8.6 |
2.9 |
3.3 |
1.7 |
2.3 |
|
Oligodendroglioma |
9450 |
1,524 |
87.9 |
88.5 |
80.1 |
81.3 |
65.7 |
68.3 |
46.8 |
51.1 |
|
Anaplastic oligodendroglioma |
9451, 9460 |
256 |
75.0 |
75.8 |
56.8 |
58.1 |
38.1 |
40.5 |
24.5 |
27.7 |
|
Ependymoma/anaplastic ependymoma |
9391-9393 |
1,038 |
85.9 |
86.3 |
78.6 |
79.5 |
65.9 |
67.9 |
55.3 |
59.0 |
|
Mixed glioma |
9382 |
664 |
83.6 |
84.1 |
71.9 |
72.8 |
54.4 |
56.3 |
39.0 |
42.3 |
|
Glioma malignant, NOS |
9380 |
2,346 |
46.6 |
47.7 |
33.9 |
35.5 |
25.3 |
28.5 |
19.3 |
24.7 |
|
Neuroepithelial |
9381, 9423, 9430, 9443 |
235 |
59.5 |
60.2 |
47.3 |
48.5 |
37.0 |
39.4 |
28.5 |
32.7 |
|
Malignant neuronal/glial, neuronal and mixed |
8680-8682, 8690, 8693, 9490-9491, 9500,
9505-9506, 9522-9523 |
154 |
77.1 |
77.4 |
63.6 |
64.0 |
51.3 |
52.1 |
46.3 |
47.5 |
|
Embryonal/primitive/ medulloblastoma |
8963, 9363-9364, 9470-9473, 9501-9503 |
1,269 |
79.8 |
80.0 |
70.2 |
70.4 |
53.6 |
54.0 |
45.2 |
45.9 |
|
Total: All brain and CNSb |
8000-9989 |
33,896 |
50.0 |
50.9 |
35.0 |
36.4 |
25.6 |
28.2 |
19.5 |
24.2 |
aRates are an estimate of the percentage of patients alive at
one, two, five and ten years, respectively.
bIncludes histologies not listed in this table. Brain
lymphomas, olfactory tumors of the nasal cavity, and malignant tumors of the
pituitary and pineal glands are excluded.
Abbreviation used: SEER, Surveillance, Epidemiology, and End
Results.
Disclaimer
The Central Brain Tumor Registry of the United States (CBTRUS) is a not-for-profit corporation which gathers and disseminates epidemiologic data on primary brain tumors in order to facilitate research and establish awareness of the disease. CBTRUS makes no representations or warranties, and gives no other assurances or guarantees, express or implied, with respect to the accuracy or completeness of the data presented. The information provided in this website is not intended to assist in the evaluation, diagnosis or treatment of individual diseases. Persons with questions regarding individual diseases should contact their own physician to obtain medical assistance.